(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote In favor of Your Number one Savvy Beds - 2Study finds humans were making fire 400,000 years ago, far earlier than once thought
- 3Dirty soda started as a Mormon alternative to booze. Now it's everywhere.
- 4Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby.
- 5Which Brilliant Home Gadget Can't You Reside Without?
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- An Excursion Through Renowned Western Network programs
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 5 Instructive Toy Brands for Youngsters
- Language Learning Applications for Voyagers
- Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- Manual for 6 well known Amusement Park
- Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
